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ABSTRACT
Objective: The purpose of this prospective study is to 
investigate the impact of adding active vitamin D 
metabolite to hormone replacement therapy (HRT) in 
the treatment of osteoporosis in early postmenopausal 
women.
Methods: Fifty-two naturally postmenopausal women 
receiving either 0.625 mg conjugated estrogen with 2.5 
mg medroxyprogesterone acetate daily for 1 2  months 
or 0.50 pgr one alpha cholecalciferol in addition to 
0.625 mg conjugated estrogen with 2.5 mg 
medroxyprogesterone acetate daily for 1 2  months.
Results: Bone mass density (BMD) increases 
significantly in both treatment groups at 1 2  months not 
only in proximal femur but in the lumbar spine as well. 
In the HRT + alpha calcidiol group, the percentage of 
change in BMD for the proximal femur was 17.32 ± 
22.41 and 15.02 ± 10.05 for the lumbar spine. In the 
HRT alone treatment group the percentage of change 
in BMD was 12.21 ± 12.81 and 9.44 ± 8.01 for the 
proximal femur and the lumbar spine respectively.
Conclusion: Addition of vitamin D metabolite seemed 
to potentiate the BMD elevating effect of HRT even 
though the positive trend in the BMD change was not 
statistically significant in one year.
Key W ords: Alpha calcidiol, Bone Density, 
Hormone Replacement Therapy.
INTRODUCTION
Osteoporosis is a systemic skeletal disease 
characterised by low bone mass and microarthitectural 
deterioration of bone tissue, with a consequent 
increase in bone fragility and susceptibility to fracture. 
The positive effect of hormone replacement therapy on 
reducing bone loss in estrogen deficient women is well 
defined and non controversial.
Vitamin D deficiency is common in elderly people, in 
whom it causes decreased intestinal calcium 
absorption and secondary hyperparatyroidism, which 
may result in increased bone turnover, bone loss and 
fractures or even osteomalacia (1). Supplementation 
with vitamin D and calcium may reduce bone loss and 
may decrease hip fractures especially among elderly 
women (2). Hence, vitamin D supplementation has 
been recommended for prevention of osteoporosis in 
the elderly. However, the literature is very scarce on 
the bone effects of vitamin D supplementation in early 
postmenopausal women. Alpha calcidiol which is a 
synthetic anologue of active vitamin D in the form of 
one-alpha- hydroxycholecalciferol, is attracting 
considerable interest in the prevention of osteoporosis. 
The purpose of the present study is to investigate the 
impact of adding active vitamin D metabolite to HRT in 
the treatment of osteoporosis in early postmenopausal 
women.
METHODS
Fifty two postmenopausal women who presented to 
the Marmara University Hospital Menopause clinic 
between December 1995 and February 1997 were 
recruited for this prospective study after informed 
consent was obtained. All subjects were natural 
menopausal women and 2 - 1 1  years had elapsed since 
their last menstruation. The study was approved by the 
Institutional Review Board of the Marmara University 
School of Medicine. Patients were free of any systemic 
disease and none of them had used any medication in 
the previous 6  months. Each patient underwent a 
complete physical and gynecological examination, in 
addition, hepatic and renal functions analyses were 
made and baseline serum TSH, PTH, T3 , T4, total 
calcium, phosphate, total protein and albumin were 
measured. Anthropometric measurements were 
recorded initially (height, weight, waist, hip). The bone 
mineral density at the lumbar spine (L2 -L4 ) and at the 
left femoral neck was determined by the trained 
personnel using dual energy X ray absorptiometry ( 
Dexa, Lunar DPX, Madison, Wl, U.S.A.). Coefficients
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of variation for the instrument were 1% for the spine 
and 2.2% for the proximal femur in vivo. Scans were 
analyzed with 1.3 version software. These tests were 
repeated at the end of one year. Patients were 
randomly assigned using a computer program to 
receive either 0.625 mg conjugated estrogen with 2.5 
mg medroxyprogesterone acetate or 0.50 pgr one 
alpha cholecalclferol in addition to 0.625 mg 
conjugated estrogen with 2.5 mg 
medroxyprogesterone acetate daily for 12 months. All 
patients received 500 mg calcium lactate gluconate 
daily. Values were expressed as means ± SD. Paired 
and unpaired Student’s t tests were used for statistical 
analyses.
RESULTS
The characteristics of the 52 postmenopausal women 
are shown in Table I. There is no statistically 
significant difference in demographic characteristics 
between patients taking HRT and those taking HRT 
plus alfa calcidiol. The serum calcium, phosphorus, 
creatinin, total protein, albumin, alkaline phosphatase
Table I. Demographic characteristics of the patients.
(ALP), thyroid stimulating hormone (TSH) and 
parathyroid hormone (PTH) baseline levels and 12 
months levels after initiation of treatment in both 
groups are shown in Table II. None of the parameters 
were significantly different between the groups. BMD 
at L2-L4 and proximal femur before and after 12 
months of treatment in both groups are demonstrated 
in Table III. BMD increased significantly in both 
treatment groups at 1 2  months not only in proxirrfal 
femur but at lumbar level as well. In the HRT + alfa 
calcidiol treatment group the percentage of change in 
BMD for the proximal femur was 17.32 ± 22.41 and
15.02 ± 10.05 for the lumbar spine. In the HRT alone 
treatment group, the percentage of change in BMD 
were 12.21 ± 12.81 and 9.44 ± 8.01 for the proximal 
femur and the lumbar spine respectively. The 
percentage of change in BMD in both groups is shown 
in Table IV. The percentage of change in BMD at the 
end of 1 2  months was not significantly different 
between the treatment groups both at the femur and 
lumbar site. However, there was a trend towards a 
better response with alpha calcidiol + HRT treatment 
group which did not achieve significance.
PATIENTS CONTROL GROUP TREATMENT GROUP P VALUE
Mean 51.84+2.8 51 73±2.6
Age(years) p>0.05
Range 44-59 42-62
Years for Mean 6.2±1.87 5.8+1.59
menopause p>0.05
Range 2-10 2-11
BMI Mean 38.3±3.8 37.6±3.7
(Body Mass Index) p>0.05
(kg/m2) Range 24.6-45.4 22.4-48.2
Values expressed as meantdeviation.
Table II. Comparison of bone turnover related serum markers
HRTGROUP (n:26) HRT + ALFA CALCIDIOL GROUP (n:26)
Baseline alter 12 months Baseline alter 12 months
Calcium mg/dl 9.12 ± 0.69 9.23 ± 0.69-*- 9.36 ± 0.58 9.48 ± 0.634
Phosphorus mg/dl 3.35 ±0.59 3.32 ± 0.27# 3.15 ±0.44 3.24 ± 0.404
Creatinin mg/dl 0.671 ± 0.20 0.694 ± 0.224 0.673 ±0.19 0.703 ±0.184
Tot. prot mg/dl 8.05 ±0.95 8.21 ±0.674 7.85 ± 1.0 8.10 ±0.984
Albumin mg/dl 4.1 ± 0.67 4.05 ±0.954 4.26 ±0.82 4.18 ±0.794
ALP mg/dl 62.54 ± 32.54 62.06 ± 32.274 61.33 ±35.04 62.10 ± 34.754
TSH mlU/ml 1.17 ±1.6 1.32 ± 0.884 1.06 ± 1.42 1.19 ± 1.374
PTH pg/ml 38.64 ± 19.71 41.24 ± 19.844 42.24 ±20.32 39.56 ± 19.564
Values are the mean with standard deviations
♦ : not significant
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Table III. Comparison of bone mass densities of groups at baseline and after 12 months
HRT GROUP (n:26) HRT + ALFA CALCIDIOL GROUP (n:26)
Baseline after 12 months Baseline after 12 months
Proximal Femur gr/cm3 0.790 ±0.130 0.867 ±0.128* 0.771 ± 0.136 0.881 ± 0.130*
Lumbar Vertebrae gr/cm3 0.900 ±0.123 0.961 ± 0.125* 0.919 ±0.128 1.025 ± 0.135*
values are the mean with standard devations 
*  significant
Table IV. Percentage of increase in bone mass densities within groups after 12 months
HRT GROUP (n:26) HRT + ALFA CALCIDIOL GROUP (n:26) p value
Proximal Femur 12.21 (±12.81)% 17.32 (±22.41)%* p=0.21
Lumbar Vertebrae 9.44 (±8.01)% 15.02 (±10.05)%* p=0.15
values are the mean with standard deviations 
♦ : not significant
DISCUSSION
Prevention of postmenopausal bone loss by HRT is 
widely accepted. Vitamin D supplementation is an 
accepted treatment of osteomalacia and has been 
suggested as a non hormonal alternative in the 
prevention of osteoporotic fractures in elderly people. 
Chapuy et al, demonstrated lower incidence of 
peripheral and femoral fractures in patients receiving 
800 IU vitamin Dg daily when compared to control 
group, in a 36 months follow up study (2). Lips et al, 
stated that 400 IU vitamin D3 daily produced a slight 
increase in femoral bone density, which did not show 
any influence on the incidence of hip fractures (3). The 
decline in estrogen levels during menopause, causes, 
a transient reduction in serum calcitriol concentrations 
and calcium absorption (4). It appears that, a direct 
reduction in 1 alpha hydroxylase capacity seems to be 
less involved than a reduction in the activity of factors 
that normally stimulate the conversion of 25(OD)D to 
1,25 (OH)2 D (5). Alfa calcidiol is a chemical precursor 
of calcitriol within the body and rapid transformation by 
liver via 25-hydroxylation in bone into the most active 
metabolite of vitamin D exemplifies the pro-drug 
technique (1). It has been confirmed previously in 
animal models that the half life of 1,25 (OH^Dg, is 
prolonged following alfa calcidiol administration (6 ).
The efficacy and safety of alfa calcidiol in treating 
postmenopausal osteoporosis were consistently and 
impressively demonstrated by several authors. In 
controlled clinical studies, it has been demonstrated 
that alfa calcidiol can increase vertebral bone mass 
between 2% and 6 % after 2 years (7,8). Another 
prospective, placebo controlled, randomised study in 
6 6  postmenopausal women demonstrated that alfa 
calcidiol combined with calcium increased radial bone 
density 2% whereas in placebo group BMD decreased 
by 7.8% at the end of 3 years (9). Francis et al, 
reported that neither vitamin D nor one alpha 
hyroxylated vitamin Dg derivatives were effective in 
the treatment of postmenopausal osteoporosis (1 0 ). 
Heikkinen et al, stated that there was no significant 
difference in BMD between patients taking HRT and 
HRT plus vitamin D (8 ). In another study; Francis et al 
found that postmenopausal women treated over 7 
days with 0.5 pgr alfa calcidiol daily display statistically 
significant superior increase in calcium absorption 
compared with women treated with 40 pgr 25(OH)D3
(11). Komulainen et al, reported that vitamin D 
supplementation with or without HRT could not prevent 
either lumbar or femoral bone loss in 464 non 
osteoporotic early postmenopausal women (1 2 ). 
Tuppurainen et al, in a 4 year prospective study 
showed that, addition of vitamin D to HRT increases
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femoral neck BMD significantly, whereas lumbar spine 
BMD did not differ in comparison to HRT alone group
(13). The vit D serum concentrations of the women 
were not measured in the present study. However, 
relative impairment of calcium absorption among early 
postmenopausal osteoporotic women is quite likely, 
which usually results in increased bone turnover. 
Addition of vitamin D to HRT might correct suboptimal 
serum concentrations of vitamin D. Our results showed 
that both HRT and HRT combined with alfa calcidiol 
increases bone densities at lumbar spine and femoral 
neck significantly at the end of 1 year. It appears that 
the addition of alfa calcidiol to HRT potentiates the 
BMD elevating effect of HRT even though the positive 
trend did not achieve significance. However, the 
additional cost of the treatment has to be considered. 
The limitations of this study are, having relatively 
smaller groups and shorter follow up periods. Future 
studies with larger groups and longer follow up periods 
will enlighten the efficacy of adding alfa calcidiol to 
HRT in preventing osteoporosis and reducing fractures 
in early postmenopausal women.
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